Literature DB >> 9675447

Pharmacodynamic interactions of antibiotics alone and in combination.

J J Schentag1, L C Strenkoski-Nix, D E Nix, A Forrest.   

Abstract

Clinical trials show that the area under the inhibitory curve (AUIC) is predictive of antibacterial killing rates in patients with nosocomial pneumonia and is useful for predicting clinical or microbiological outcomes and making dosage adjustments with beta-lactams, quinolones, aminoglycosides, and vancomycin. The AUIC values of two antibiotics are additive, and since antibiotics are often given in combination, determining the AUIC for antibiotic combinations could potentially predict the microbiological outcomes for patients given these combinations. To further address this question, mathematical modeling was used to study in vitro pharmacokinetic and pharmacodynamic interactions of the antimicrobials piperacillin and ciprofloxacin. These agents were also studied in vivo in healthy volunteers. Blood samples were obtained for analysis of serum drug concentrations, and serum inhibitory titers were determined against eight common bacterial pathogens, chosen to reflect the range of MIC values to ciprofloxacin and piperacillin. Additive AUIC relationships predictive of bacterial killing rates were typical in patients given these antibiotics in combination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675447     DOI: 10.1086/514621

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Antimicrobial resistance--pharmacological solutions.

Authors:  E Rubinstein
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

Review 4.  Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.

Authors:  Marin H Kollef; Yoav Golan; Scott T Micek; Andrew F Shorr; Marcos I Restrepo
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

5.  Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo.

Authors:  J W Mouton; M L van Ogtrop; D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 6.  Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.

Authors:  A Sánchez-Navarro; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

7.  Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.

Authors:  G R Matzke; R F Frye; M S Joy; P M Palevsky
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 8.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 9.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Céline Vidaillac; Steve N Leonard; Helio S Sader; Ronald N Jones; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.